Loading...
Infant Bacterial Therapeutics AB (IFTBF, $4.78) was a top loser over the last three months, falling -4 to $4.78 per share. A.I.dvisor analyzed 755 stocks in the Biotechnology Industry for the 3-month period ending December 10, 2025, and found that of them (5) exhibited an Uptrend while of them (4) demonstrated a Downtrend.
Industry Biotechnology